Apnimed, Inc. is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The Company's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.
Back to dashboard
Company Information
About this company
Key people
Paul Jai Sekhri
Independent Chairman of the Board
Francois Beaubien
Director
Isaac Cheng
Director
Chris Dimitropoulos
Director
Gary L. Sender
Director
Dennis P. Molnar
President, Chief Operating Officer
Kevin R. Lind
Chief Executive Officer, Director
Lawrence G. Miller
Co-Founder, Independent Vice Chairman of the Board
Michael Kelly
Chief Financial Officer
John Cronin
Chief Medical Officer
Graham Goodrich
Chief Commercial Officer
Steven Spector
Chief Legal Officer and Head of Corporate Affairs
Barry Wohl
Chief Business Officer
Click to see more
Key facts
- Shares in issue41.63m
- EPICAPMD
- ISINUS03770Y1073
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$739.36m
- Employees65
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.